- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 8 - Treatment's Financial Constraints
The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.
The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.
Dr Sugarbaker says of the 4 major cancers ̶ including lung, breast, colon and prostate ̶ lung cancer is by far the number one killer, especially in women. For NSCLC, conversations between providers and payers need to focus on where multi-modality treatment makes sense for certain patients.
Dr Langer comments that increasingly, insurers will approve 1 maintenance drug or another, but not 2. This is largely driven by cost concerns. Even will oral agents, costs are still exorbitant. It can be difficult to find or offer financial support for patients.
Dr Sugarbaker adds that the progress that is been made in NSCLC depends on treatment. “You can’t evaluate new therapies without coverage for particularly protocol therapies.” He says the “onus” is on insurers and managed care organizations to continue supporting innovative therapies in a protocol setting because that is how they have made and will continue to make progress.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
June 23rd 2025This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Read More
